AEGiS-Reuters: Malawi Says It Will Cut AIDS Drugs Prices by 20%

Reuters, Ltd.Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Click here to return to Reuters main menu


DonateNow


Malawi Says It Will Cut AIDS Drugs Prices by 20%

Reuters NewMedia - Monday December 3, 2001


LILONGWE (Reuters) - Malawi's government said on Monday it would slash the price of antiretroviral AIDS drugs by at least 20% early next year to make them more affordable for an estimated one million Malawians living with the disease.

The cost of a month's supply of the drugs "will go down again by April. They should go down to 2,000 Malawi kwacha ($30.20) or below," said Professor George Liwomba, chairman of the country's Antiretroviral Drug Committee.

It is the latest cut in a series of reductions by the government. In March, the price of a month's course of AIDS drugs was halved from $155 and reduced further in July to the current price of $40 or 2,650 kwacha a month.

The National AIDS Commission estimates that one in every 10 Malawians lives with HIV, the virus that causes AIDS, and over 350,000 have died of the deadly disease since the first reported case in 1985.

Approximately 250 Malawians are infected every day with HIV, and life expectancy has dipped to 39 years from 48 years.

Liwomba said the government would continue to subsidise the cost of antiretrovirals to make them affordable, but analysts have said the projected price is still too high for the country's poor, most of whom live on less than a dollar a day.

Several of the world's biggest drug firms have cut prices on their AIDS drugs in a bid to make them more affordable in Africa, which has more than 28 million people living with the deadly disease.
011203
RE011207


Copyright © 2001 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.   Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .